Cells from people with systemic sclerosis keep responding strongly to TGF-β1 because they fail to turn off their TGF-β receptor, while healthy cells turn it off after stimulation, leading to prolonged collagen production and fibrosis.
Evidence from Studies
Supporting (1)
Community contributions welcome
Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis
In people with systemic sclerosis, their repair cells keep reacting strongly to a growth signal (TGF-β1) because they can't turn off the signal receiver, unlike healthy cells that turn it off after use—this leads to too much scar tissue buildup.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether TGFBR1 dysregulation and sustained SMAD/AKT/ERK signaling in MSCs is a consistent molecular signature across SSc populations and correlates with disease severity.
A systematic review and meta-analysis of all published studies measuring TGFBR1 expression and SMAD3/AKT/ERK phosphorylation in MSCs from SSc patients versus controls after TGF-β1 stimulation, with pooled standardized mean differences and subgroup analysis by disease subtype and treatment history.
Whether pharmacologically restoring TGFBR1 downregulation in SSc-MSCs reduces fibrosis in vivo.
A double-blind RCT of 100 SSc patients with skin fibrosis, randomized to receive oral TGFBR1 kinase inhibitor or placebo for 24 weeks, with primary outcome of change in mRSS and secondary outcomes including TGFBR1 expression and pSMAD3 levels in serially collected MSCs.
Whether sustained TGFBR1 signaling in baseline MSCs predicts progression of fibrosis in early SSc.
A prospective cohort of 180 patients with early SSc, collecting MSCs at diagnosis and measuring TGFBR1 expression and pSMAD3/pAKT levels after TGF-β1 stimulation; primary outcome is change in lung fibrosis (FVC) and skin score over 3 years.
Whether sustained TGFBR1 signaling is more pronounced in SSc-MSCs from patients with diffuse disease versus limited disease.
A case-control study comparing TGFBR1 expression and downstream signaling (pSMAD3, pAKT, pERK) in MSCs from 50 diffuse cutaneous SSc patients and 50 limited cutaneous SSc patients, matched for age, sex, and disease duration, after 6-day TGF-β1 exposure.
Whether TGFBR1 signaling intensity in MSCs correlates with current fibrosis burden in SSc patients.
A cross-sectional analysis of MSCs from 150 SSc patients, measuring TGFBR1 expression and pSMAD3 levels after TGF-β1 stimulation and correlating with mRSS, FVC, and serum procollagen III levels at the time of bone marrow aspiration.